MX2012001464A - Sensibilidad a inhibidores de la angiogenesis. - Google Patents
Sensibilidad a inhibidores de la angiogenesis.Info
- Publication number
- MX2012001464A MX2012001464A MX2012001464A MX2012001464A MX2012001464A MX 2012001464 A MX2012001464 A MX 2012001464A MX 2012001464 A MX2012001464 A MX 2012001464A MX 2012001464 A MX2012001464 A MX 2012001464A MX 2012001464 A MX2012001464 A MX 2012001464A
- Authority
- MX
- Mexico
- Prior art keywords
- vegfr
- determining
- present
- gene
- variant alleles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G01N33/575—
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La presente invención se relaciona con métodos para mejorar la supervivencia total en un paciente que padece de una enfermedad por neoplasia maligna metastásica o una enfermedad implicando angiogénesis fisiológica y patológica mediante el tratamiento con un inhibidor de la angiogénesis, como bevacizumab, determinando la presencia de uno o más alelos variantes del gen del receptor 1 del factor de crecimiento endotelial vascular (VEGFR-1). La presente invención se invención adicionalmente proporciona métodos para mejorar la superviviencia libre de progresión en un paciente que padece de una enfermedad por neoplasia maligna metastásica o una enfermedad implicando angiogénesis fisiológica y patológica mediante el tratamiento con un inhibidor de la angiogénesis, como bevacizumab, determinando la presencia de uno o más alelos variantes del gen VEGFR-1. La presente invención también proporciona métodos para evaluar la sensibilidad de un paciente a un inhibidor de la angiogénesis determinando la presencia de uno o más alelos variantes del gen VEGFR-1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09167184 | 2009-08-04 | ||
| PCT/EP2010/004761 WO2011015348A2 (en) | 2009-08-04 | 2010-08-03 | Responsiveness to angiogenesis inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012001464A true MX2012001464A (es) | 2012-05-08 |
| MX344247B MX344247B (es) | 2016-12-09 |
Family
ID=42797289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012001464A MX344247B (es) | 2009-08-04 | 2010-08-03 | Sensibilidad a inhibidores de la angiogenesis. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20120195858A1 (es) |
| EP (3) | EP2894231B1 (es) |
| JP (2) | JP5886197B2 (es) |
| KR (1) | KR20130079303A (es) |
| CN (1) | CN102575288A (es) |
| AU (1) | AU2016203889A1 (es) |
| BR (1) | BRPI1015134A2 (es) |
| CA (1) | CA2766523A1 (es) |
| ES (1) | ES2536195T3 (es) |
| IL (1) | IL216798A (es) |
| MX (1) | MX344247B (es) |
| SG (1) | SG178209A1 (es) |
| WO (1) | WO2011015348A2 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140064923A (ko) * | 2011-08-31 | 2014-05-28 | 에프. 호프만-라 로슈 아게 | 혈관신생 억제제에 대한 반응성 |
| MX2014006186A (es) * | 2011-11-23 | 2014-07-14 | Hoffmann La Roche | Capacidad de respuesta a los inhibidores de la angiogenesis. |
| EP3663414B1 (en) * | 2013-06-13 | 2023-11-22 | Roche Diagnostics GmbH | Statistical analysis for non-invasive y chromosome aneuploidy determination |
| CN104195231B (zh) * | 2014-07-24 | 2017-01-18 | 益善生物技术股份有限公司 | 贝伐单抗疗效相关基因表达检测液相芯片试剂盒 |
| WO2017091473A1 (en) | 2015-11-24 | 2017-06-01 | Indiana University Research & Technology Corporation | Composition for blocking angiogenesis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0004232D0 (en) * | 2000-02-24 | 2000-04-12 | Zeneca Ltd | Diagnostic method |
| CA2558753A1 (en) * | 2004-03-01 | 2005-09-15 | University Of Chicago | Polymorphisms in the epidermal growth factor receptor gene promoter |
| US20060057626A1 (en) * | 2004-09-03 | 2006-03-16 | Nichol Geoffrey M | Assessment of CTLA-4 polymorphisms in CTLA-4 blockade therapy |
| WO2007109571A2 (en) * | 2006-03-17 | 2007-09-27 | Prometheus Laboratories, Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
| WO2007109183A2 (en) * | 2006-03-20 | 2007-09-27 | Novartis Ag | Mutations and polymorphisms of fms-related tyrosine kinase 1 |
-
2010
- 2010-08-03 US US13/388,840 patent/US20120195858A1/en not_active Abandoned
- 2010-08-03 EP EP15151581.4A patent/EP2894231B1/en not_active Not-in-force
- 2010-08-03 JP JP2012523243A patent/JP5886197B2/ja not_active Expired - Fee Related
- 2010-08-03 BR BRPI1015134A patent/BRPI1015134A2/pt not_active IP Right Cessation
- 2010-08-03 MX MX2012001464A patent/MX344247B/es active IP Right Grant
- 2010-08-03 WO PCT/EP2010/004761 patent/WO2011015348A2/en not_active Ceased
- 2010-08-03 ES ES10744513.2T patent/ES2536195T3/es active Active
- 2010-08-03 EP EP10744513.2A patent/EP2462242B1/en not_active Not-in-force
- 2010-08-03 SG SG2012007092A patent/SG178209A1/en unknown
- 2010-08-03 CA CA2766523A patent/CA2766523A1/en not_active Abandoned
- 2010-08-03 EP EP16194527.4A patent/EP3153592A1/en not_active Withdrawn
- 2010-08-03 KR KR1020127005749A patent/KR20130079303A/ko not_active Ceased
- 2010-08-03 CN CN2010800349421A patent/CN102575288A/zh active Pending
-
2011
- 2011-12-06 IL IL216798A patent/IL216798A/en not_active IP Right Cessation
-
2016
- 2016-02-05 JP JP2016020377A patent/JP2016144449A/ja active Pending
- 2016-06-10 AU AU2016203889A patent/AU2016203889A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3153592A1 (en) | 2017-04-12 |
| CN102575288A (zh) | 2012-07-11 |
| AU2016203889A1 (en) | 2016-06-30 |
| AU2010281043A1 (en) | 2012-01-19 |
| WO2011015348A3 (en) | 2011-03-31 |
| IL216798A0 (en) | 2012-02-29 |
| MX344247B (es) | 2016-12-09 |
| EP2462242B1 (en) | 2015-04-01 |
| SG178209A1 (en) | 2012-03-29 |
| CA2766523A1 (en) | 2011-02-10 |
| EP2894231A1 (en) | 2015-07-15 |
| WO2011015348A2 (en) | 2011-02-10 |
| JP5886197B2 (ja) | 2016-03-16 |
| US20120195858A1 (en) | 2012-08-02 |
| IL216798A (en) | 2016-05-31 |
| KR20130079303A (ko) | 2013-07-10 |
| EP2462242A2 (en) | 2012-06-13 |
| EP2894231B1 (en) | 2017-01-04 |
| ES2536195T3 (es) | 2015-05-21 |
| BRPI1015134A2 (pt) | 2016-04-19 |
| JP2016144449A (ja) | 2016-08-12 |
| JP2013501015A (ja) | 2013-01-10 |
| AU2010281043B2 (en) | 2016-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR077026A1 (es) | Marcadores de riesgo para enfermedades cardiovasculares | |
| AR083357A1 (es) | Metodo para el diagnostico, pronostico y tratamiento de la metastasis de cancer de mama | |
| ES2654340T3 (es) | Marcadores para cáncer endometrial | |
| WO2012006589A3 (en) | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling | |
| MX2009002936A (es) | Biomarcadores de la modulacion de objetivo, eficacia, diagnostico, y/o pronostico para los inhibidores de raf. | |
| CR20120406A (es) | Identificación de mutación lkb1 como un biomarcador predictivo para sensibilidad a inhibidores de tor cinasa | |
| BR112014025269A2 (pt) | método para o prognóstico e tratamento de metástase de câncer | |
| MX2019003811A (es) | Metodos para predecir el desenlace clinico del cancer. | |
| MX2013002084A (es) | Biomarcadores y metodos de tratamiento. | |
| MX2016003245A (es) | Calreticulina mutante para la diagnosis de malignidades mieloides. | |
| MX2013014153A (es) | Biomarcadores paa terapia de inhibidor de hedgehog. | |
| EP4219760A3 (en) | Methods, compositions, and devices utilizing microrna to determine physiological conditions | |
| WO2010091049A3 (en) | Diagnosis and treatment of cancer | |
| CR9315A (es) | Metodos y sistemas para el diagnostico, pronostico y seleccion del tratamiento de la leucemia | |
| BR112016007864A2 (pt) | método para a prognose e tratamento de metástase de câncer | |
| MX2012001464A (es) | Sensibilidad a inhibidores de la angiogenesis. | |
| CY1119451T1 (el) | Αντισωμα που αναγνωριζει τον ανθρωπινο ανασταλτικο παραγοντα λευχαιμιας (lif) και η χρηση των anti-lif αντισωματων στη θεραπεια παθησεων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο | |
| MX343801B (es) | Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer de mama. | |
| EA201270606A1 (ru) | Новое противоопухолевое применение кабазитаксела | |
| WO2012109632A3 (en) | Crown-like structures as a biomarker for cancer risk and cancer prognosis | |
| MX2012007009A (es) | Método para diagnosticar un tumor maligno. | |
| GB2480980A (en) | Methods for predicting cancer response to EGFR inhibitors | |
| MX2015002749A (es) | Metodo diagnostico y terapeutico para el cancer dirigido a moleculas expresadas en celulas madre cancerosas. | |
| MX2015001788A (es) | Metabolitos de metionina predicen la evolución agresiva del cáncer. | |
| WO2012166700A3 (en) | Molecular profiling of a lethal tumor microenvironment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |